The chair of the CDC’s Advisory Committee on Immunization Practices (ACIP), Kirk Milhoan, announced a comprehensive reevaluation of all U.S. vaccine recommendations, telling the New York Times the committee will reexamine risks and benefits across products. Milhoan framed the effort as a shift toward individualized decision-making and questioned established messaging around vaccine mandates, comments that mark a sharp departure from ACIP’s recent practice. Public-health experts and academic critics have warned this move could inject political influence into technical vaccine guidance and complicate immunization schedules used by clinicians and schools. ACIP’s review comes amid high-profile leadership changes at HHS and broader scrutiny of federal vaccine policy; any formal changes to the childhood immunization schedule would trigger operational shifts for manufacturers, distributors, and public-health programs.